Clocort

Quick links to important sections

Clocort

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clocort

What is Clocort? Definition and Pharmacological Class

Property Description
Active Ingredients Chloramphenicol, Dexamethasone
Form Sterile Solution or Suspension (Drops)
Pharmacological Class Antibiotic-Corticosteroid Combination
Common Use Context Ophthalmic and Otic Conditions
Origin Synthetic Compounds

Clocort is a specialized pharmaceutical preparation defined as a fixed-dose combination product containing two distinct, synthetic active ingredients: Chloramphenicol and Dexamethasone. The product's identity is established by its dual-agent composition, placing it within the therapeutic category of antibiotic-corticosteroid combinations. This classification, which is clinically recognized by major pharmacopoeias, signifies that the preparation is engineered to address conditions where both an infectious component and significant inflammation are present. Dexamethasone belongs to the corticosteroid pharmacological class, a category of compounds used for their anti-inflammatory properties.


Composition and Origin: Synthetic Dual-Action Agents

The composition of Clocort relies on two potent, synthetically derived compounds, which work together to achieve bimodal action. Chloramphenicol is an amphenicol-class antibacterial and acts primarily as a broad-spectrum bacteriostatic agent, meaning it inhibits the essential protein synthesis necessary for bacterial growth. The other agent, Dexamethasone, is a potent synthetic glucocorticoid that works by modulating the body’s inflammatory response at the cellular level, suppressing symptoms like swelling and redness. This combination is typically used in situations requiring swift mitigation of inflammatory symptoms alongside bacterial control, such as acute superficial ear or eye issues.


Drug Form and Administration Context

Clocort is formulated as a sterile liquid preparation, typically a solution or suspension, intended solely for topical administration. The preparation is specifically designed for use as ophthalmic (eye drops) or otic (ear drops) preparations, distinguishing it from systemic medications. This localized approach is crucial, ensuring the precise delivery of high concentrations of the active ingredients directly to the surface tissues of the eye or the outer ear canal, maximizing local therapeutic effect while minimizing systemic exposure.

Regulatory References

  1. NIH MedlinePlus on Topical Therapies

What side effects are possible with Clocort?

Possible Side Effects and Safety Information

The safety profile for the combination of Chloramphenicol and Dexamethasone is documented by regulatory authorities, outlining both common local effects and rare, serious risks associated with the active components. The adverse reactions are classified primarily by the organ system affected and the frequency observed in clinical data.


Officially Documented Adverse Reactions

The most frequent adverse reactions are local and transient. Patients commonly experience stinging or a burning sensation immediately following application to the eye or ear. Localized discomfort or irritation is also classified within the common range of effects.

Serious Adverse Reactions and Safety Constraints

The official labeling identifies several serious adverse reactions, particularly related to the duration of treatment with the corticosteroid component, Dexamethasone:

  • Ocular Complications: Prolonged use is explicitly associated with an increased risk of Intraocular Pressure (IOP) elevation (potentially leading to glaucoma) and the formation of posterior subcapsular cataracts.
  • Systemic Risk: The Chloramphenicol component carries a rare, potentially fatal, risk of blood dyscrasias, including aplastic anemia, which has been reported following both systemic and topical use.
  • Tissue Perforation: The use of the corticosteroid is a safety constraint in conditions causing thinning of the cornea or sclera, as this increases the hazard of perforation.

Safety Considerations by Population and Time

The risk of IOP monitoring difficulty in pediatric patients is noted in official documentation, especially when the corticosteroid is used for ten days or longer. These duration-related patterns and population-specific notes structure how regulatory agencies communicate the overall safety profile of the medicine.

Overdose and Emergency Response

The official regulatory profile for Clocort (Chloramphenicol + Dexamethasone) overdose primarily addresses the risks associated with chronic over-application of the corticosteroid component and the risks of accidental oral ingestion of the contents.

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations Manifestations of Hypercortisolism (Cushing's syndrome features) resulting from prolonged systemic absorption of the Dexamethasone component. Acute over-application may cause local irritation. Transient gastrointestinal symptoms may occur after accidental oral ingestion.
Physiological systems affected (as stated in label) Hypothalamic-Pituitary-Adrenal (HPA) axis suppression (Dexamethasone) and potential blood dyscrasias, including aplastic anemia (Chloramphenicol), are cited as serious risks in regulatory documents.
Dose-related or exposure-related factors Chronic intensive or prolonged topical use is cited as the primary risk factor for HPA axis suppression. Accidental ingestion of the vial contents is cited as an overdose circumstance.
Population-specific overdose notes Pediatric patients may have a greater susceptibility to HPA axis suppression and systemic toxicity due to increased systemic absorption risk.

Overdose Classifications (High-Level)

Classification Official Regulatory Wording
Severity classification Reversible HPA axis suppression is cited as a serious effect of chronic overuse. Aplastic anemia is cited as a rare but severe risk.
Overdose-context constraints The likelihood of acute overdose from topical application is minimal. There is no specific antidote known for the active substances.

Official Overdose Statements:

  • Seek immediate medical attention is required following accidental ingestion of the drug, particularly if ingested by children.
  • For acute ocular overdose, the affected eye(s) should be flushed with lukewarm water.
  • Management for any overdose scenario is defined as symptomatic and supportive treatment.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by focusing on the rare potential for serious systemic effects, such as HPA axis suppression, stemming from chronic misuse of the topical corticosteroid component. Regulators mandate that urgent medical attention must be sought immediately following accidental oral ingestion of the product's contents. Management is officially described as symptomatic and supportive due to the confirmed absence of a specific antidote.

Therapeutic Uses of Clocort

The primary therapeutic utility of Clocort (Chloramphenicol + Dexamethasone) is relevant in contexts marked by increased discomfort or tension, applied in addressing conditions where significant inflammation is complicated by, or highly susceptible to, bacterial infection in the eyes or ears. The combination is commonly used in conditions presenting with acute episodes, including severe forms of conjunctivitis, keratitis, and otitis externa. It is also relevant when supportive symptom management is appropriate following ocular injury or surgery. The combination is used in therapeutic areas where symptomatic relief of inflammation in the anterior eye segment is needed, particularly when bacterial infection is present or suspected.

The medication helps address symptom clusters that create noticeable functional strain, specifically focusing on pronounced redness, tissue swelling, and purulent discharge associated with inflammatory or irritative states. Symptomatic relief helps patients cope more steadily with difficult episodes by easing the impact of these visible and physically distressing manifestations.

“This approach is relevant in contexts involving heightened systemic burden, supporting patients during difficult episodes by easing distress.”


Quick Fact: Relief for Dual Pathology

Focus Area Symptom Categories Relieved Clinical Scenario Example
Ophthalmic Pronounced redness, swelling, ocular discharge Post-surgical inflammation or acute conjunctivitis
Otic Swelling in the ear canal, discomfort, ear discharge Severe otitis externa

Eligibility and Restrictions for Use

Who Can and Cannot Use Clocort? Official Eligibility Rules

Official regulatory guidelines define specific populations that are either contraindicated (must not use) or require restricted use of Clocort (Chloramphenicol + Dexamethasone topical).


Absolute Non-Eligibility (Contraindicated)

The medicine is formally contraindicated and must not be used by individuals who meet the following criteria:

  • Hypersensitivity: Known allergy to chloramphenicol, dexamethasone, or any product component.
  • Infection Type: The presence of viral infections (such as herpes simplex keratitis, vaccinia, or varicella), fungal diseases, or mycobacterial infections in the eye or ear structures.
  • Age/Life Stage: Infants less than 28 days old and nursing women (due to the risk of systemic exposure to Chloramphenicol).
  • Medical History: Patients with a pre-existing history of bone marrow suppression or hepatic impairment (for some formulations).

Populations Requiring Caution or Restricted Use

Specific populations require close medical supervision or conditional use due to documented risks:

  • Pediatric Use: Use in children under 2 years of age is generally not established and recommended only in exceptional, closely monitored cases.
  • Organ Function: Patients with impaired liver or renal function may require caution due to the risk of Chloramphenicol accumulation.
  • Ocular Integrity: Individuals with a history of glaucoma, cataracts, or conditions causing corneal/scleral thinning must use the product with great caution due to the Dexamethasone component.

What should I know about interactions with other medicines?

The interaction profile for the combination product Clocort is officially documented by regulatory authorities, focusing on pharmacokinetic alterations, additive organ toxicity, and specific administration requirements. The information below describes documented interaction patterns.

Contraindicated and Avoided Combinations

Co-administration must be avoided with other medicinal products liable to depress bone marrow function due to the associated hematological risk from Chloramphenicol. Additionally, live attenuated vaccines should not be used when Dexamethasone is administered at immunosuppressive doses. Topical bactericidal antibiotics must also be avoided with Chloramphenicol due to potential functional interference.

Pharmacokinetic and Exposure Alterations

Chloramphenicol is documented as an inhibitor of certain liver enzymes, specifically CYP2C9, CYP2C19, and CYP3A4. This inhibition may increase the systemic exposure of co-administered substrates such as Warfarin or Calcineurin Inhibitors. Conversely, co-administration with strong CYP3A4 Inhibitors (e.g., Ritonavir) decreases the clearance of Dexamethasone, which can lead to increased systemic exposure and the risk of adrenal suppression. Caution is also noted for patients with impaired renal or hepatic function due to the potential for drug accumulation.

Administration and Substance Restrictions

A mandatory timing rule applies to ophthalmic use: if more than one topical product is administered, they must be spaced at least 5 minutes apart, with eye ointments administered last. The use of Dexamethasone with topical NSAIDs may increase the potential for corneal healing problems. Furthermore, Chloramphenicol may decrease the therapeutic response to Iron and Vitamin B12 supplements.

Mechanism of Action

How Clocort Works


Bimodal Action: Inhibition of Bacterial Growth

The mechanism is defined by bimodal action, engaging two distinct biological pathways: microbial protein synthesis and host inflammatory signaling. The antibacterial component acts by binding to the 50S ribosomal subunit inside the microbial cell, blocking the peptidyl transferase enzyme. This molecular blockade arrests the bacterial protein synthesis pathway, leading directly to the physiological effect of microbial growth arrest.


Glucocorticoid Receptor-Mediated Anti-Inflammatory Cascade

The corticosteroid component functions as an agonist at the intracellular Glucocorticoid Receptor (GR), initiating a genomic cascade. This action upregulates proteins like Lipocortin-1 which inhibits Phospholipase A2 (PLA2), thereby suppressing the production of inflammatory mediators from the Arachidonic Acid Cascade (prostaglandins and leukotrienes). This mechanism leads to the attenuation of local inflammation, suppressing the physiological outcomes of edema and erythema.


Mechanistic Coordination and Functional Constraints

The dual mechanism operates with coordinated action, achieving simultaneous microbial growth suppression and inflammatory pathway dampening. The anti-inflammatory component suppresses cellular proliferation and immune activity, which is a mechanism that functionally results in delayed wound healing.

Dosage and Administration Information

How to Use Clocortolone Pivalate Cream

The following instructions for Clocortolone Pivalate Cream (0.1%) outline the administration guidelines for this medication.

Administration Protocol

Guideline Instruction
Route For topical dermatologic use only. Avoid ophthalmic, oral, or intravaginal contact.
Frequency Apply three times a day (TID).
Application Apply sparingly to the affected skin areas.
Technique The cream must be rubbed in gently until it disappears.

Special Procedural Conditions

To ensure correct usage, specific conditions must be followed:

  • Occlusive Dressings: The treated area must not be bandaged, covered, or wrapped as to be occlusive, unless specifically directed by a physician. This helps manage the rate of absorption.
  • Eye Contact: Avoid contact with the eyes during application.
  • Missed Dose: If a dose is missed, apply it as soon as you remember. If it is nearly time for the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not apply extra or double doses to make up for the missed one.
  • Pediatric Use: Administration to children must be limited to the least amount compatible with an effective treatment regimen. Parents of infants being treated in the diaper area must be advised not to use tight-fitting diapers or plastic pants, as these act as occlusive dressings.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clocort


Evidence for Use in Ophthalmic Infections and Inflammation

Research on this combination in the eye includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. This body of work was studied for conditions where inflammation is linked to or suspected of being complicated by bacterial infection, such as acute conjunctivitis or certain forms of keratitis. Studies monitored physiological strain or stress linked to acute changes, including the measurement of ocular redness, swelling, and discharge. Researchers also monitored the rate of microbiological cure to see if patterns of bacterial clearance were observed in the study populations.

The findings describe patterns observed in the studies over the short-term treatment period. For instance, studies report how symptoms evolved in the observed populations, observing changes in the markers of inflammation and infection. However, the evidence base often includes trials of similar products, and in cases like acute conjunctivitis, trials observed that symptoms in many populations can resolve spontaneously, which contributes to the complexity of isolating the specific contribution of the fixed combination.

Evidence for Use in Acute Outer Ear Infections (Otitis Externa)

For conditions associated with acute or disruptive episodes in the ear, such as otitis externa, research involves RCTs and meta-analyses that compare various topical regimens. The studies explored outcomes related to physical discomfort and daily functioning or activity level. Researchers monitored key endpoints like the rate of measured change in clinical signs (such as the disappearance of disease signs) and the time taken for patient-reported outcomes describing perceived discomfort (such as ear pain and discharge) to evolve.

Data show patterns related to symptom evolution over the short, defined study intervals, which typically span 7 to 14 days. This heterogeneity across comparative studies means that while the fixed combination was evaluated in this context, certain comparative evidence against the newest alternative treatments is still emerging.

Frequently Asked Questions (FAQ)

Common questions about Clocort (FAQ)

Q: What is Clocort used for besides the primary condition listed?

A: According to regulatory documents, Clocort is indicated for treating inflammation in the front part of the eye or ear where a corticosteroid is indicated. This includes situations where inflammation is either complicated by a bacterial infection or where a bacterial infection is suspected.

Q: How quickly does Clocort typically start to provide relief?

A: The clinical label does not specify an exact number for the time it takes to see the first signs of relief. However, official information states that patients should contact their doctor if symptoms do not begin to improve within a few days of starting treatment.

Q: Is Clocort meant for short-term use, or can it be taken long-term?

A: Official guidance states that the treatment period should generally not exceed 10 days. Regulatory documents caution against prolonged use due to the potential for serious eye conditions, such as elevated intraocular pressure (which can lead to glaucoma) and the formation of cataracts.

Q: Does Clocort cause weight gain or changes in appetite?

A: Because the drug contains Dexamethasone, which can be absorbed systemically, side effects associated with oral corticosteroids, such as weight gain, may rarely occur. This effect is more commonly observed when the medication is used in higher doses or for prolonged periods.

Q: Can Clocort affect sleep patterns or cause insomnia?

A: Official side effect reporting indicates that the systemic absorption of the corticosteroid component may rarely be associated with psychiatric effects. These disturbances could potentially include issues with sleep patterns or insomnia.

Q: Does Clocort interact with common over-the-counter pain medications?

A: According to the official labeling, using the corticosteroid component alongside topical non-steroidal anti-inflammatory drugs (NSAIDs), which are common pain relievers, may increase the chance of problems with corneal healing. This warning is related to topical administration in the eye, as stated in the product information.

Q: Is it safe to consume alcohol in small amounts while using Clocort?

A: Regulatory documents state that it may be advisable to avoid or limit the intake of alcohol while using this medicine. This is primarily because alcohol may affect the body's natural response to infection or potentially worsen certain systemic side effects.

Q: Is Clocort safe for use in older adults (seniors)?

A: According to regulatory information, no specific dose adjustment is required for the older adult population (seniors). No specific data comparing the use of the medicine in the elderly population to younger patients has been reported in the official labeling.

Q: What is the pregnancy risk classification for Clocort?

A: Official documents state that the Dexamethasone component has shown a potential to cause harm to a fetus in animal studies. Therefore, the product should be used during pregnancy only if the potential benefit is judged to justify the potential risk to the fetus.

Q: How soon after stopping Clocort will the drug be cleared from the system?

A: The regulatory documents generally do not provide an exact time frame for when the medication will be completely cleared from the body. Clearance time depends on the individual half-lives (the time it takes for half the drug to leave the body) of the active ingredients.

Q: Does Clocort build up in the body over time?

A: Official warnings advise caution for individuals with impaired liver (hepatic) or kidney (renal) function because there is a potential for the drug's components to accumulate in the body under these specific conditions. Regulatory information primarily addresses the potential for accumulation in the context of impaired liver or kidney function.

Q: Can Clocort affect energy levels or cause fatigue?

A: Official safety documentation notes that the Chloramphenicol component is associated with a rare but serious risk of blood disorders (bone marrow depression). A possible symptom related to this rare condition is unusual tiredness or weakness (fatigue).

Q: Are headaches a commonly reported side effect when starting Clocort?

A: Headache has been mentioned in reports following the marketing of Dexamethasone, but it is typically not listed among the most frequent local side effects for this specific combination product. The most common side effects are usually local stinging or burning.

Q: Are there any specific foods that should be avoided while taking Clocort?

A: According to official product labeling, there are no specific food restrictions or dietary changes that must be followed while using this topical medication.

Q: Can Clocort affect the accuracy of blood sugar or cholesterol tests?

A: Regulatory information notes that Dexamethasone, if absorbed systemically, can affect metabolism and may lead to elevated blood sugar levels. Therefore, patients with diabetes are advised to discuss blood sugar monitoring with a healthcare professional.

Q: Can Clocort affect fertility in men or women?

A: Official monographs for the Chloramphenicol component indicate that there is no evidence from the available data to suggest that this agent reduces fertility in either men or women.

Q: Is Clocort considered a habit-forming or addictive substance?

A: According to official regulatory classifications, Clocort is not classified as a controlled substance and is not listed as having any habit-forming or addictive potential.

Q: Does Clocort need to be taken with food for better absorption?

A: Since this medication is formulated as a sterile solution intended solely for topical use (in the eye or ear), administration with food to aid gastrointestinal absorption is not applicable.

Q: Is Clocort a controlled substance?

A: Official government regulatory bodies have not classified this product as a controlled substance under the Drug Enforcement Administration (DEA) schedule.

Q: Can Clocort affect a person's mood or cause increased anxiety?

A: Systemic absorption of the Dexamethasone component may, in rare instances, be associated with psychiatric effects, including changes in mood such as mild depression or mental confusion.

Q: Does using Clocort cause the body to develop 'drug tolerance'?

A: Regulatory documents discuss that prolonged or repeated use of the corticosteroid component may lead to suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. This physiological change can make the body reliant on the medication.

Q: Is it okay to use Clocort if I am currently taking birth control pills?

A: Official information advises caution if the product is used alongside strong CYP3A4 inhibitors, which is a drug class that includes some hormonal contraceptives. Using these together may decrease the clearance of Dexamethasone, which could lead to increased exposure.

Q: What happens if Clocort is stored outside of the recommended temperature range?

A: The official product labeling strictly requires that Clocort be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and kept from freezing. Storing the medicine outside of these required temperature conditions or exposing it to light may affect the product's effectiveness and stability.

Q: Why do some people experience initial stomach upset when starting Clocort?

A: Nausea and vomiting and stomach pain have been reported in safety documents as less common or rare systemic side effects following use. These effects are generally associated with systemic absorption of the active components.

Q: Does Clocort cause increased sensitivity to sunlight?

A: The official label includes a specific warning to avoid prolonged exposure to sunlight or UV radiation. This is because the product may cause increased photosensitivity, as noted in the product warnings.

Q: Can Clocort be used 'as needed' rather than continuously?

A: The regulatory dosing information specifies a fixed dosing schedule, such as administration three times a day. The fixed dosing schedule does not align with 'as-needed' administration.

Q: Is hair thinning or loss associated with Clocort use?

A: While the systemic form of the corticosteroid component is associated with certain skin and hair changes, hair thinning or loss is generally not listed as a prominent side effect for the topical formulation.

Q: What is the typical time frame to see the full therapeutic effect of Clocort?

A: Regulatory documents do not state an exact time frame for seeing the full therapeutic effect. Symptoms are typically reviewed by a healthcare provider for improvement within the short course of treatment.

Q: Can Clocort be used by athletes or those subject to anti-doping tests?

A: The Dexamethasone component is classified as a glucocorticoid, a class of substance that is often restricted or closely monitored by international sports and anti-doping authorities.

Q: Is Clocort described in official documents as affecting driving ability?

A: The official information advises that this medication may cause temporary blurring of vision. Official warnings state that patients should use caution when driving or operating heavy machinery until their vision is clear.

Q: Is it common for doctors to recommend monitoring while on Clocort?

A: Regulatory documents state that if the medicine is used for 10 days or longer, the patient should have their intraocular pressure (IOP) routinely monitored. This is done to check for potential side effects associated with prolonged corticosteroid use.

How should Clocort be stored and disposed of?

How to Store and Dispose of Clocort (Chloramphenicol and Dexamethasone Drops)

Official regulatory labeling dictates specific conditions for storing and disposing of Clocort drops.


Storage Requirements

Clocort must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F) and should not be allowed to freeze. The medicine must be protected from light by being kept in its original outer carton. Once the bottle is opened, the in-use period is limited; any remaining contents must be discarded after 28 days.


Disposal and Safety

It is mandatory to keep the product out of the sight and reach of children. Unused or expired Clocort must not be thrown away via wastewater or household waste. Users are instructed to dispose of the product in accordance with local requirements and to consult a pharmacist for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clocort found in:

A-Z Index: